source
- Regeneron posts mid-stage POTS data; Kyverna completes CAR-T filingPlus, news about Merck KGaA, Rezolute, Vir, Orakl and Cellectis. Regeneron’s mid-stage POTS data: The biotech’s monoclonal antibody, baloncibart, given at 450 mg led to an average 11.4-beat-per-min…
- Cellectis could cut 70% of workforce in shift to in vivo therapiesCellectis’ business transformation could cost around 160 global employees their jobs. The company has stopped enrollment in its two CAR T programs as it focuses on trials of its in vivo candidates.BioSpace · 2d ago↗ source
- Eli Lilly’s Mounjaro and Merck’s oral PCSK9 inhibitor win FDA nod amid string of cardiovascular trial setbacks